A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer
SigMA-predicted HRD may better identify patients likely to benefit from olaparib as compared to the current FDA label. Larger studies are needed for further validation.
Authors
- Gitanjali Lakshminarayanan (ORCID: https://orcid.org/0000-0002-6386-8478)
- Guruprasad Ananda (ORCID: https://orcid.org/0000-0001-6697-3479)
- Heather M. McClure (ORCID: https://orcid.org/0000-0002-4441-5609)
- Peter J. Park (ORCID: https://orcid.org/0000-0001-9378-960X)
- Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
- Ziad Bakouny (ORCID: https://orcid.org/0000-0003-1906-5704)
- Daniel Boiarsky (ORCID: https://orcid.org/0009-0007-5740-9244)
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Jacob E. Berchuck (ORCID: https://orcid.org/0000-0002-7607-2428)
- D. Gulhan (ORCID: https://orcid.org/0000-0001-5419-0549)
- Rebecca Silver (ORCID: https://orcid.org/0000-0003-3730-2144)
- Alok K. Tewari (ORCID: https://orcid.org/0000-0003-2617-7499)
- Hunter Savignano (ORCID: https://orcid.org/0009-0007-9138-9363)
Institutions
- Tufts Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Emory University (US)
- Rosalind Franklin University of Medicine and Science (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- The Prostate
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1002/pros.24788
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Institutes of Health